Cancer Research and Treatment

HER-2/neu in Breast Cancer: Is Consensus Reached in Standard Testing?: Seung Sook Lee; Cancer Res Treat. 2003;35(2):87-89. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.87

PDF

3,228 View
15 Download

Passive Smoking and Lung Cancer: Hwangbo Bin, Jin Soo Lee; Cancer Res Treat. 2003;35(2):90-95. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.90

Abstract PDF: Passive smoking is an important risk factor for lung cancer and its impact might be more significant than generally appreciated in Korea. We reviewed the literatures that support the biologic plausibility of Environmental Tobacco Smoke (ETS) causing lung cancer and summarized epidemiological evidences. Because ETS exposure is a preventable risk factor, more social efforts should be directed to reduce ETS exposure.

3,224 View
25 Download

Evaluation of Her-2/neu in Breast Cancer: Comparison of Immunohistochemistry and Polymerase Chain Reaction: Mi Ja Lee, Ho Jong Jeon; Cancer Res Treat. 2003;35(2):96-101. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.96

Abstract PDF: PURPOSE
In breast cancer, Her-2/neu amplification/overexpression predicts a poor clinical outcome, and enhanced survival benefits have been reported with Her-2/neu targeted therapy. Currently, there are several methods for assessing the amplification/overexpression of Her-2/neu, each having advantages and disadvantages. The aim of this work was to establish a reproducible, sensitive and specific method of testing for Her-2/neu, which could be used in diagnostic pathology laboratories. MATERIALS AND METHODS: We compared the immunohistochemistry (IHC) detection of Her-2/neu overexpression, with differential polymerase chain reaction (PCR) to assess the gene amplification of the Her-2/ neu, in 163 cases of invasive ductal carcinoma of the breast using paraffin-embedded tissue. In addition, assessment of the appropriate cut off points was established. RESULTS: The overexpression of the Her-2/neu was detected in 39 (23.9%) cases, and its amplification in 37 (22.7%) cases. The methods were positive in 21.5% of cases and negative in 74.8%. There was a 96.3% concordance between the two methods. The sensitivity and specificity of IHC, compared with PCR, were 94.6 and 96.8%, respectively. CONCLUSION: We conclude that the automation of PCR-based Her-2/neu testing approaches is expected to play an increasing role in the future of Her-2/neu testing. Also, we have demonstrated that IHC is a sensitive and specific method for assessing Her-2/neu stati in breast cancer, compared to PCR. The current study indicates that moderate, or strong, complete membrane staining in> or =10% of tumor cells provides an appropriate cut off point compared with PCR.

3,194 View
22 Download

A Clinical Analysis of PTEN Expressions in Breast Cancers: Hang Ju Cho, Jeong Soo Kim, Kee Hwan Kim, Chang Hyeok Ahn, Woo Chan Park, Se Jeong Oh, Sang Seol Jung, Keun Woo Lim, Seock Ah Im; Cancer Res Treat. 2003;35(2):102-108. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.102

Abstract PDF

PURPOSE
The PTEN gene, a novel tumor suppressor, is localized to chromosome 10q23.3 and shares extensive homology with the cytoskeletal protein, tensin. A high frequency of mutations at the PTEN locus has been described in a variety of neoplasms including breast cancer and Cowden Disease. However, the role of PTEN alterations and its association with clinicopathological factors have not been well established. We investigated the relationship between the PTEN expression and clinicopathological factors.
MATERIALS AND METHODS
Formalin-fixed, paraffin-embedded tissues from 105 women with breast cancer were evaluated for the PTEN expression and were scored semi-quantitatively based on staining intensity and distribution. Results were statistically compared with clinicopathological factors.
RESULTS
Forty-seven (45%) of the 105 breast cancers had a loss of the PTEN expression. In the recurrent group, 19 of 32 (59%) patients showed a loss of the PTEN expression, whereas in the non-recurrent group, only 28 of 73 (38%) patients showed a loss of the PTEN expression. The loss of PTEN expression correlated with estrogen receptors (ER) (p=0.027), recurrence (p=0.046), HER-2/neu overexpression (p=0.016), disease-free survival (p=0.0163), and overall survival (p=0.0357). In particular, when HER-2/ neu was overexpressed, the overall survival rate correlated with the loss of PTEN expression statistically (p=0.0454), whereas when HER-2/neu was negative, there was no correlation (p=0.9808). Progesterone receptor (PR) and disease stage had no relationship with the PTEN expression. CONCLUSION: Our results support that PTEN plays a role as a tumor suppressor in breast cancer and is a prognostic factor in predicting recurrence.

Citations

Citations to this article as recorded by

The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients
Feng Xu, Chao Zhang, Jianxiu Cui, Jun Liu, Jie Li, Hongchuan Jiang
Medicine.2017; 96(36): e8000. CrossRef

3,649 View
32 Download
1 Crossref

The Prognostic Significance of the Overexpression of HER-2/ neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2/neu Antibody on Cell Growth in the Gastric Carcinoma Cell Lines: Seock Ah Im, Kyung Eun Lee, Eunmi Nam, Seung Hyun Nam, Do Yeun Kim, Chu Myong Seong, Hae Young Park, Woon Sup Han, Ju Young Seoh, Soon Nam Lee; Cancer Res Treat. 2003;35(2):109-116. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.109

Abstract PDF

PURPOSE
The HER2 gene encodes a 185-kd transmembrane glycoprotein receptor (p185(HER2)) that has partial homology with the epidermal growth factor receptor (EGFR) and shares intrinsic tyrosine kinase activity. The HER2 gene has been found to be amplified in various human cancers and to be associated with poor prognosis. The authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor. MATERIALS AND METHODS: We evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years). Protein expression was analysed by immunohistochemical staining in paraffin embedded tissues with monoclonal antibody for p185(HER2). To explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed. RESULTS: p185(HER2) overexpression correlates positively with lymph node metastasis (p=0.002), distant metastasis (p=0.01), AJCC classification (p=0.01), higher relapse rate p=0.001), and a tendential association with the pT stage (p=0.054). p185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008). Patients with overexpression of p185(HER2) were found to have significantly lower relapse-free (p=0.003) and overall survival (p= 0.0004) than patients without overexpression. Among several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2). Trastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression. DNA fluorescence flow cytometry of propidium iodide-stained nuclei showed a reduction in the fraction of the S phase following treatment with trastuzumab. CONCLUSIONS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism. This suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.

Citations

Citations to this article as recorded by

A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
A. V. Avgustinovich, S. G. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. G. Frolova, O. V. Cheremisina
Siberian journal of oncology.2024; 23(1): 170. CrossRef
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Feng‐Hua Wang, Lin Shen, Jin Li, Zhi‐Wei Zhou, Han Liang, Xiao‐Tian Zhang, Lei Tang, Yan Xin, Jing Jin, Yu‐Jing Zhang, Xiang‐Lin Yuan, Tian‐Shu Liu, Guo‐Xin Li, Qi Wu, Hui‐Mian Xu, Jia‐Fu Ji, Yuan‐Fang Li, Xin Wang, Shan Yu, Hao Liu, Wen‐Long Guan, Rui‐Hu
Cancer Communications.2019; 39(1): 1. CrossRef
The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer
Hyunho Kim, Sang Mi Ro, Ji Hyun Yang, Joon Won Jeong, Ji Eun Lee, Sang Young Roh, In-Ho Kim
The Korean Journal of Internal Medicine.2018; 33(5): 990. CrossRef
Potential Prognostic Significance of p185HER2 Overexpression with Loss of PTEN Expression in Gastric Carcinomas
Seock-Ah lm, Kyung Eun Lee, Eunmi Nam, Do Yeun Kim, Joo-Ho Lee, Ho-Seong Han, Ju-Young Seoh, Hae-Young Park, Min-Sun Cho, Woon Sup Han, Soon Nam Lee
Tumori Journal.2005; 91(6): 513. CrossRef

4,489 View
52 Download
4 Crossref

Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma: Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jun Suk Kim; Cancer Res Treat. 2003;35(2):117-122. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.117

Abstract PDF

PURPOSE
Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been used with 5-fluorouracil (5-FU) continuous infusion for the treatment of advanced gastric carcinoma. However, continuous 5-FU infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer.
MATERIALS AND METHODS
A total of 22 patients was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and leucovorin 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled patients received 81 courses of chemotherapy and the median number of course per patient was three with a range of one to six. Five of 21 patients achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding patients, three had unresectable perigastric lymph-nodes, one patient had a ovarian metastasis, and one patient had a peritoneal metastasis respectively. Main toxicities were neutropenia and nausea/vomiting. Grade 3 and 4 neutropenia were observed in 4 patients (18%) and grade 3 nausea/vomiting were observed in 5 patients (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of heptaplatin, UFT-E and leucovorin has a comparable efficacy with those of previously reported heptaplatin and intravenous regimen of 5-FU and controllable toxicity in advanced gastric carcinoma. Further study with large patient population is warranted to determine the usefulness of this regimen.

Citations

Citations to this article as recorded by

Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
Xi Hu, Fangyuan Li, Nabila Noor, Daishun Ling
Science Bulletin.2017; 62(8): 589. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef
A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
Cancer Research and Treatment.2005; 37(4): 208. CrossRef
Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
Cancer Research and Treatment.2004; 36(3): 182. CrossRef

4,391 View
23 Download
4 Crossref

Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer: Yong Tai Kim, Joo Hyuk Sohn, So Hun Kim, Sun Young Rha, Chul Kim, Jae Kyung Roh, Byung Soo Kim, Woo Ick Jang, Hyun Cheol Chung; Cancer Res Treat. 2003;35(2):123-129. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.123

Abstract PDF

PURPOSE
This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1, 000 mg/m2 intravenous (IV) 24 hour infusion (Day 1~3), leucovorin 20 mg/m2 (Day 1~3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks. RESULTS: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4~24), the median time to response was 8 weeks (range: 8~20) the median time to progression was 30.0 weeks (95% CI: 16.3~43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7~70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity. CONCLUSION: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients.

Citations

Citations to this article as recorded by

The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy
Sang-Joon Shin, Min-Kyoung Kim, Kyung-Hee Lee, Myung-Soo Hyun, Sang Woon Kim, Sun Kyo Song, Sung-Hwa Bae, Hun-Mo Ryoo
Cancer Research and Treatment.2004; 36(6): 367. CrossRef

4,273 View
29 Download
1 Crossref

Prognosis of Malignant Obstructive Jaundice Following Surgery for Gastric Carcinoma: Jae Hyun Song, Ki Young Yoon, Sang Ho Lee; Cancer Res Treat. 2003;35(2):130-134. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.130

Abstract PDF

PURPOSE
Obstructive jaundice is a rare presentation, but is an ominous prognostic sign in patients undergoing surgery for a gastric carcinoma. Therefore, we investigated the prognosis of malignant obstructive jaundice following surgery for a gastric carcinoma. MATERIALS AND METHODS: Thirty-eight patients, with an extrahepatic biliary obstruction due to a metastatic gastric carcinoma, were retrospectively studied to determine their demographics, clinical features, laboratory finding, pathological characteristics and survival. RESULTS: Between January 1996 and April 2000, 2401 patients underwent operations for gastric cancer, of which 38 (1.6%) were found to have obstructive jaundice. The mean age was 55.9 +/- 10.7 years, and the sex ratio (male: female) was 3.2: 1. The median interval between the previous gastrectomy and the presentation of jaundice was 10.1 8.9 months. The levels of total bilirubin and direct bilirubin were 16.5 +/- 6.5 and 12.0 +/- 4.4, respectively. The most common site of the obstruction was the common bile duct (65%). An antrumal location, poorly differentiated stage IV gastric cancer was common associated with obstructive jaundice. A percutaneous transhepatic biliary drainage was a commonly used treatment modality. When the clinical and laboratory findings were presented to a Cox regression analysis, the P values of the time interval and albumin were 0.019 and 0.057, respectively. CONCLUSION: The time interval between a previous gastrectomy, the presentation of jaundice and albumin level were found to be independent risk factors for predicting the survival.

Citations

Citations to this article as recorded by

EUS-guided hepaticojejunostomy in patients with history of total gastrectomy: a multicenter retrospective feasibility study (with video)
Daniele Balducci, Jean-Philippe Ratone, Marion Schaefer, Sébastien Godat, Enrique Perez-Cuadrado-Robles, Solene Hoibian, Yanis Dahel, Meddy Dalex, Jean-Baptiste Chevaux, Fabrice Caillol, Marc Giovannini
Gastrointestinal Endoscopy.2024;[Epub] CrossRef
Surgical treatment of ductal biliary recurrence of poorly cohesive gastric cancer mimicking primary biliary tract cancer: a case report
Edoardo Poletto, Andrea Ruzzenente, Giulia Turri, Simone Conci, Serena Ammendola, Claudio Luchini, Aldo Scarpa, Alfredo Guglielmi
Journal of Surgical Case Reports.2022;[Epub] CrossRef
Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer
Takeshi Okamoto
World Journal of Gastroenterology.2022; 28(10): 985. CrossRef

3,976 View
31 Download
3 Crossref

Irinotecan Combined with Bolus Fluorouracil, Continuous Infusion Fluorouracil, and Low-Dose Leucovorin Every Two Weeks in Patients with Oxaliplatin Pretreated Metastatic Colorectal Cancer: Hyuk Chan Kwon, Sung Hyun Kim, Jae Seok Kim, Hyo Jin Kim; Cancer Res Treat. 2003;35(2):135-140. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.135

Abstract PDF

PURPOSE
To determine the efficacy and tolerance of irinotecan in combination with fluorouracil (5-FU) plus leucovorin (LV) in patients whose disease has progressed after treatment with an oxaliplatin-based therapy. MATERIALS AND METHODS: Thirty-two patients were enrolled in this study from January 2000 to October 2002. Each patient's disease had progressed under oxaliplatin containing regimen. The new treatment consisted of irinotecan 150 mg/m2 as a 90-minute infusion on day 1, LV 20 mg/m2 bolus, given intravenously, immediately followed by a bolus of 5-FU, 400 mg/m2, and a 22-hour continuous infusion at 600 mg/m2 on day 1 through day 2. Treatment was repeated at 2-week intervals. RESULTS: Among the assessable 30 patients, median age was 50 years (range: 29~67), and dominant sites of metastasis were liver, lung, and lymph nodes. The objective response rate was 20%; all patients registered partial responses; 14 patients were stabilized (46.7%); and 10 had progression of disease (33.3%). Median progression-free survival was 24.6 weeks and median survival was 39.6 weeks. For the 210 cycles analyzed, NCI-CTC grades 3 and 4 hematologic toxicities were leucopenia (10%) and neutropenia (5%). Frequently occurring grade 3~4 non-hematologic adverse reactions were nausea/ vomiting (10%), diarrhea (6.7%), stomatitis (6.7%), and alopecia (10%). There were no treatment-related deaths.
CONCLUSIONS
TIrinotecan in combination with 5-FU plus LV regimen is safe and effective in oxaliplatin-pretreated advanced colorectal cancer patients.

Citations

Citations to this article as recorded by

Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats
David Dahlgren, Evelina Rosenqvist, Per M. Hellström, Peter Nygren, Fredrik Kullenberg, Karsten Peters, Markus Sjöblom, Hans Lennernäs
Basic & Clinical Pharmacology & Toxicology.2022; 131(6): 536. CrossRef
Effect of an Irinotencan, 5-Fluorouracil, and Leucovorin Combination Chemotherapy (FOLFIRI) in Metastatic Colorectal Cancer
Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek
Journal of the Korean Society of Coloproctology.2007; 23(5): 333. CrossRef
A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer
Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Research and Treatment.2006; 38(2): 72. CrossRef
Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer
Myung-Ah Lee, Jae-Ho Byun, Byoung-Young Shim, In-Sook Woo, Jin-Hyung Kang, Young Seon Hong, Kyung Shik Lee, Myung Gyu Choi, Suk Kyun Chang, Seong Taek Oh, Sung Il Choi, Doo Suk Lee
The Korean Journal of Internal Medicine.2005; 20(3): 205. CrossRef
Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line Therapy
Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn
Cancer Research and Treatment.2004; 36(4): 235. CrossRef

4,839 View
18 Download
5 Crossref

Patterns of Failure and Prognostic Factors in Anal Cancer Treated with Radiotherapy: Kyoung Ju Kim, Jong Hoon Kim, Eun Kyung Choi, Seung Do Ahn, Sang Wook Lee, Jin Cheon Kim, Chang Sik Yu, Hee Cheol Kim, Je Hwan Lee, Tae Won Kim; Cancer Res Treat. 2003;35(2):141-147. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.141

Abstract PDF: PURPOSE
To analyze the patterns of failure and prognostic factors affecting the local control and survivals in anal cancer treated with definitive radiotherapy, and to find the most effective treatment modality. MATERIALS AND METHODS: Thirty consecutive patients, with primary cancers of the anal canal, were treated using radiotherapy, both with and without 5-FU based concurrent chemotherapy. According to the AJCC tumor stage, six patients hadwere stage I, 11 had stage II, 2 had stage IIIA, and 11 had stage IIIB tumors. The median radiation dose was 45 Gy (30-72 Gy), and with 23 patients receivinged concurrent chemotherapy (5-FU and mitomycin C in 12 patients, 5-FU and cisplatin in 7, and other drugs in 4). The Mmedian follow up period was 43 months, (ranginge, from 8- to 99 months). RESULTS: Among the 1630 patients who16 were treated without surgical resection beforeprior to the radiotherapy, and a complete remission was observed in 12 patients (75%), a partial remission in 3 (19%), and a local progression in the other one patient. The Llocal failures, including persistent disease, were observed in 10 (33%), and the patients with higher T-stages (T3-4) had higher rates of local failure rates (T1-2, 21% vs. T3-4, 72%, p=0.03). Distant metastases were found in 4 patients (13%). The five year survival and disease free survival rates were 64% and 53%, respectively. The factors which affectinged the 5 year local relapse free survival were T-stage (74.9% in T1-2 vs. 28.6% in T3-4, p=0.01), and the existence of a gross tumor beforeprior to radiotherapy (84.6%, no residual vs. 45.1% with residual, p=0.03).
CONCLUSION
A Llocal recurrence was the major failure pattern in anal cancers, and the factors affecting a local failure were the T-stage and tumor volume beforeprior to radiotherapy. A Rradiation dose around 45 Gy was sufficient to control tumors of the earlier T stage tumors, but a higher dose should be considered for with more advanced lesions.

6,268 View
29 Download

Differential Sensitivity of Taxol-induced Apoptosis in U2OS and SaOS2 Osteogenic Sarcoma Cells: Jung Hye Kim, Byung Rho Chin, Seong Yong Kim, Jae Ryong Kim, Suk Hwan Baek; Cancer Res Treat. 2003;35(2):148-153. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.148

Abstract PDF

PURPOSE
Taxol (Paclitaxel) is a new generation of chemotherapeutic drug proven to be effective in the treatment of many cancers. In this study, to further demonstrate the differential effect of the tumor suppressor gene, p53, on the Taxol-induced apoptosis in osteogenic sarcoma cell lines, we used p53-defected SaOS2 cells and wild type p53-expressed U2OS cells. MATERIALS AND METHODS: The cell viability was measured by the XTT assay. To examine whether the differential expressions of p53, in U2OS and SaOS2 cells, were associated with Taxol-induced apoptosis, DNA fragmentation assays were performed on both cytosolic and genomic DNA. Since the cleavage of poly (ADP-ribose) polymerase (PARP) is primarily responsible for apoptosis, the cleavage of PARP, and the expression of cyclin B1, polo-like kinase, Bax, Bcl-xL, Bcl-2 in U2OS and SaOS2 cells were compared by Western blot analyses. RESULTS: The cell viability of the p53-defected SaOS2 cells was markedly decreased with Taxol treatment. Whereas, the cell viabilities due to 6-mercaptopurine and adriamycin were no different between the U2OS and SaOS2 cells. Treatment with Taxol induced a ladder- like pattern of DNA fragments, which is a biochemical hallmark of apoptosis, consisting of multiples of approximately 180-200 base pairs, in a dose-dependent manner in the SaOS2 cells, but insignificantly with the U2OS cells. When the cells were treated with Taxol, the 89 kDa cleavage product of PARP clearly appeared as a function of time in the SaOS2 cells, but not in the U2OS cells. The Taxol-induced apoptosis in p53 defected-osteogenic sarcoma cells was associated with the PARP cleavage as a result of the increased activity of caspase 3, and the high expressions of cyclin B1 and PLK. Bax, as a proapoptotic factor, was increased in the SaOS2cells, but the Bcl-xL and Bcl-2 were decreased when the cells were exposed to 10miceoM Taxol. CONCLUSION: From these results, it was concluded that p53-defected SaOS2 cells are much more sensitive to Taxol-induced apoptosis than p53-expressed U2OS cells.

Citations

Citations to this article as recorded by

Imatinib-Functionalized Galactose Hydrogels Loaded with Nanohydroxyapatite as a Drug Delivery System for Osteosarcoma: In Vitro Studies
Paulina Sobierajska, Benita Wiatrak, Paulina Jawien, Maciej Janeczek, Katarzyna Wiglusz, Adam Szeląg, Rafal J. Wiglusz
ACS Omega.2023; 8(20): 17891. CrossRef
Programmed cell death, redox imbalance, and cancer therapeutics
Xiaofeng Dai, Danjun Wang, Jianying Zhang
Apoptosis.2021; 26(7-8): 385. CrossRef
High-Content, High-Throughput Screening for the Identification of Cytotoxic Compounds Based on Cell Morphology and Cell Proliferation Markers
Heather L. Martin, Matthew Adams, Julie Higgins, Jacquelyn Bond, Ewan E. Morrison, Sandra M. Bell, Stuart Warriner, Adam Nelson, Darren C. Tomlinson, Maria A. Deli
PLoS ONE.2014; 9(2): e88338. CrossRef
The Time‐Dependent Serial Gene Response to Zeocin Treatment Involves Caspase‐Dependent Apoptosis in HeLa Cells
Jooyeon Hwang, Young‐Youl Kim, Sungjin Huh, Junghee Shim, Chan Park, Kuchan Kimm, Dong Kug Choi, Tae‐Kyu Park, Soonhag Kim
Microbiology and Immunology.2005; 49(4): 331. CrossRef
Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
Eun-Kyoung Yim, Jun-Sang Bae, Seung-Bak Lee, Keun-Ho Lee, Chan-Joo Kim, Sung-Eun Namkoong, Soo-Jong Um, Jong-Sup Park
Cancer Research and Treatment.2004; 36(6): 395. CrossRef

4,594 View
64 Download
5 Crossref

Gene Expression Profiling of Non-Small Cell Lung Cancer: Mee Sook Roh, Hyuk Chan Kwon, Jin Sook Jeong, Dae Cheol Kim, Choon Hee Son, Soo Keol Lee, Phil Jo Choi, Jae Ik Lee, Ki Nam Lee, Hyo Jin Kim, Jin Han Yoon, Tae Ho Hwang; Cancer Res Treat. 2003;35(2):154-160. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.154

Abstract PDF

PURPOSE
cDNA microarray provided a powerful alternative, with an unprecedented view scope, in monitoring gene expression levels, and led to the discovery of regulatory pathways involved in complicated biological processes. This study was performed to gain better understanding of the molecular mechanisms underlying the carcinogenesis and progression of lung cancer. MATERIALS AND METHODS: Using a cDNA microarray, representing 4, 600 cDNA clusters, we studied the expression profiles in 10 non-small cell lung cancer (NSCLC) samples and the adjacent noncancerous lung tissues form the same patients. The alterations in the levels of gene expression were confirmed by reverse-transcription PCR in 10 randomly selected genes.
RESULTS
Genes that were differently expressed in the cancerous and noncancerous tissues were identified. One hundred and nine genes (of which 68 were known) and 69 cDNAs (of which 32 were known) were up- and down-regulated in>70% of the NSCLC samples, respectively. In the cancerous tissues, the genes related to the cell cycle, metabolism, cell structure and signal transduction, were mostly up-regulated. Furthermore, we identified a few putative tumor suppressor genes that had previously been proposed by other workers. CONCLUSIONS: These results provide, not only a new molecular basis for understanding the biological properties of NSCLC, but also useful resources for the future development of diagnostic markers and therapeutic targets for NSCLC.

Citations

Citations to this article as recorded by

Expression of double‐stranded RNA‐activated protein kinase in small‐size peripheral adenocarcinoma of the lung
Mee Sook Roh, Ju Young Kwak, Su Jin Kim, Hyun Wook Lee, Hyuk Chan Kwon, Tae Ho Hwang, Phil Jo Choi, Young Seoub Hong
Pathology International.2005; 55(11): 688. CrossRef

4,088 View
34 Download
1 Crossref

A Small Cell Lung Cancer Concurrently Diagnosed with Paraneoplastic Dermatomyositis: Hyung Seok Lee, Dae Young Zang, Young Il Seo, Dong Gyu Kim, Eun Jung Kim, Jin Seok Ahn, Hye Rim Park; Cancer Res Treat. 2003;35(2):161-164. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.161

Abstract PDF

Dermatomyositis is an inflammatory myopathy, of unknown etiology, which is characterized by cutaneous rashes, accompanied by progressive and symmetric proximal muscle weakness. Especially in older people, the incidences of malignant conditions appear to be increased in dermatomyositis patients, and the prognosis is very poor. Because dermatomyositis may occur as a paraneoplastic syndrome, extensive screening tests, for an occult malignant neoplasm, should be conducted in older dermatomyositis patients. We experienced a case of small cell lung cancer, which had a very rapid and catastrophic clinical course, in a 63-year-old male patient with dermatomyositis. We report this case, and review the literature on the relationship of dermatomyositis and malignancy.

Citations

Citations to this article as recorded by

Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report
Andrew J. Beel, David S. Demos, Alfred Chung, Charles Liao, Natalie S. Lui
Journal of Cardiothoracic Surgery.2018;[Epub] CrossRef
A case report of dermatomyositis associated with small cell lung cancer
Wha-Yong Lee, Jack Kastelik, Anne Campbell, Ged Avery, Damian McGivern, Mike Lind
Tumori Journal.2012; 98(6): e158. CrossRef

4,196 View
37 Download
2 Crossref

M llerian-Type Gland Inclusions in Pelvic Lymph Nodes Mimicking Metastasis: A Case Report and Review of the Literature: Jinyoung Yoo, Hyun Joo Choi, Seok Jin Kang; Cancer Res Treat. 2003;35(2):165-167. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.165

Abstract PDF

Benign lymph node inclusions are rare, and can be mistaken for metastasis. We report, herein, a case of a 50-year-old woman who underwent a hysterectomy, with a lymphadenectomy, for an endometrial carcinoma. There was no lymph node metastasis; however, the left external and common iliac lymph nodes demonstrated a few glands, consistent with M llerian-type inclusions (endosalpingiosis). Awareness of these lesions is important to avoid either unnecessary therapy or any delay in treatment. Furthermore, pelvic and aortic lymphadenectomies may be warranted, as neoplastic transformation of preexisting metaplastic tubal-type epithelium is strongly suggested. This paper presents a case of intranodal endosalpingiosis mimicking metastasis.

Citations

Citations to this article as recorded by

Intraoperative Appearance of Endosalpingiosis: A Single-Center Experience of Laparoscopic Findings and Systematic Review of Literature
Laurin Burla, Dimitrios Rafail Kalaitzopoulos, Anna Mrozek, Markus Eberhard, Nicolas Samartzis
Journal of Clinical Medicine.2022; 11(23): 7006. CrossRef
Endosalpingiose – ein irrelevanter laparoskopischer Zufallsbefund?
Laurin Burla, Dimitrios Rafail Kalaitzopoulos, Markus Eberhard, Nicolas Samartzis
Praxis.2021; 110(14): 804. CrossRef
Primary lesions that may imitate metastatic tumors histologically: A selective review
Mark R. Wick
Seminars in Diagnostic Pathology.2018; 35(2): 123. CrossRef

3,467 View
25 Download
3 Crossref

Previous issues